ORGANIZATION

• Keidanren Calls for Review of Japan's Unique Pharmaceutical Regulations
  September 19, 2024

• Pharma Industry Prepares List of 68 Lawmakers to Support in Likely Snap Poll
  September 12, 2024

• Japan’s Generic Use Rate at 82.7% in FY2023: JGA
  August 1, 2024

• FPMAJ Renews Call to Ensure Stable Supply System to Prep for COVID Outbreak
  July 25, 2024

• Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023
  July 25, 2024

• Off-Year Scheme Drifting Away from Four-Minister Deal: JPMA Exec
  July 19, 2024

• Cancel or Postpone FY2025 Revision, or Scrap Off-Year Scheme: New JPA Chief
  July 19, 2024

• FIRM Hails Guidance on Conditional Approval of Regenerative Medicines
  July 17, 2024

• EFPIA Japan Names Yoshiaki Aono as Director General
  July 11, 2024

• Labor Union Group Urges Abolishment of Off-Year Price Revisions
  June 27, 2024

• Japan Digital Health Alliance Keen to Boost Ties with Overseas Organizations
  June 21, 2024

• JGA to Establish Study Group on Generic Industry Realignment
  June 21, 2024

• Majority of Candidates for G1 Withdrawal Scheme Not Able to Exit Market: FPMAJ Survey
  June 17, 2024

• FPMAJ Hails 2024 Reform, but Frets No Mention of Scrapping Off-Year Cuts in Honebuto Draft
  June 17, 2024

• EFPIA Japan Issues New Proposal on HTA, Calls for Transparency
  June 10, 2024

• 135 Meds Still in Lag/Loss State in Japan, JPMA Task Force Revving Up Fight
  June 5, 2024

• JPMA Pushing Industry-Academia Consortia in Non-Competitive Drug Discovery Fields
  June 5, 2024

• JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
  May 24, 2024

• New Task Force Discussing Steps to Stem Further Increase in Drug Lag/Loss: JPMA
  April 30, 2024

• JPMA Eager to Work with Regulators to Improve Guidance on Orphan Meds, PI Trials
  April 30, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• …
• Next ›
• 最終 »